---

Greetings. Hope you had a wonderful July 4 extended Holiday period.

Highlights of Deals in June 2024

1.     A consortium of Warburg Pincus and ChrysCapital will compete with TPG, Blackstone and EQT, as well as Mankind Pharma, to acquire BSV Group, formerly Bharat Serum & Vaccines Ltd, valuing it at US$1.4-1.5 Billion.

2.     Dr Reddy's to acquire Haleon's nicotine replacement therapy portfolio for 500 million pounds.(USD$ ~635 Million).

3.     Sun Pharma inks pact with Takeda to introduce gastrointestinal drug in India

4.     Torrent Pharma signs non-exclusive patent licensing pact with Takeda Pharma for Vonoprazan.

5.     Lupin acquires Sanofi brands Aarane and Nalcrom.

6.     Suven enters into definitive agreement for strategic controlling investment in Sapala.

7.     Lupin, Fuji sign agreement to commercialize Nextstellis in Vietnam, Philippines.

8.     Orchid Pharma partners with Cipla for distribution of new antibiotics across India.

9.     Sound Bioventures invests in US company NephroDI Therapeutics.

10.  AbbVie inks immune disorder drug licensing deal with China's FutureGen.

11.  Roche partners with Ascidian Therapeutics to develop gene therapies.

12.  Lilly partners with OpenAI to develop medicines for drug-resistant bacteria.

 

Aagami Updates:

1.     New Assignment received from a Past Client in Belgium.

2.     Aagami CEO Dinesh Jain successfully completed BIO International Convention 2023(June 3-6) in San Diego with 40+ one-on-one meetings with decision makers in Biotech, Pharma and Medtech. Dinesh attended the event on behalf of Aagami and its clients.

3.     Aagami VP Godwyn Francis to attend Bio-Europe in Stockholm, Sweden (Nov 4-6).

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

1.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses.

2.     Licensing: Several Biosimilars available for Partnering in multiple regions

3.     Partnering/Licensing: IP for a small molecule NSAID combination for Migraine and other indications using 505(b)(2).

4.     Seeking Acquisition /JV – Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

5. Seeking Partnering: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies.

For Acquisition:

1.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

2.     IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).

3.     Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

1. Seeking Investment: Human-derived, chimeric therapeutic peptide. Phase 2b stage in Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications.
2. Seeking US$3 million: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies.
3. Seeking US$5 million: Integrated Autoimmune company leading the Next Healthcare Revolution by Uncovering the drivers of autoimmune diseases to advance therapeutic assets.

Hope you found the content useful. We welcome your feedback and queries.